| Disease | POSSIBLE ENDOCRINE AND LIPID EFFECTS OF L-ARGININE WERE INVESTIGATED IN A DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CROSSOVER STUDY. ORAL L-ARGININE (9G) OR PLACEBO WAS GIVEN DAILY FOR 1 MO, WITH CROSSOVER TO THE ALTERNATE THERAPY AFTER A 1-MO
WASHOUT PERIOD, TO 10 POSTMENOPAUSAL WOMEN RECEIVING NO ESTROGEN. COMPARED WITH PLACEBO, L-ARGININE INCREASED GROWTH HORMONE BUT HAD NO EFFECT ON INSULIN AND CATECHOLAMINES. TOTAL CHOLESTEROL, TRIGLYCERIDE, APOLIPOPROTEIN E, AND LOW-,
VERY-LOW-, AND HIGH-D. LIPOPROTEIN CHOLESTEROL LEVELS WERE ALSO UNAFECTED. LIPOPROTEIN(A) MEASURED BY AN IMMUNOTURBIDIMETRIC METHOD WAS INCREASED BY L-ARGININE. AND THE CHANGES IN LIPOPROTEIN(A) LEVELS SIGNIFICANTLY CORRELATED WITH THE
RELATIVE INCREASE IN GROWTH HORMONE, HOWEVER, LIPOPROTEIN(A) MEASURED BY AN ELISA FAILED TO DEMONSTRATE SIGNIFICANT CHANGES. |